IMUC Key Stats
- Notable 52-Week Highs and Lows of the Day 11/26: (IMUC) (YPF) (TIF) High; (NUAN) (EBAY) Low Street Insider Nov 26
- Pre-Open Stock Movers 11/26: (ECTE) (JOSB) (WM) Higher; (VNET) (DSW) (NUAN) Lower (more...) Street Insider Nov 26
- Cedars-Sinai Brain Cancer Study Shows 50% vs 10% of Patients Alive After Five Years (IMUC) Street Insider Nov 25
- Unusual 11 Mid-Day Movers 11/25: (CAMT) (PBMD) (ARIA) Higher; (ICLD) (UNXL) (RCON) Lower Street Insider Nov 25
- ImmunoCellular (IMUC) Continues Higher After Added to Focus List at Roth Street Insider Nov 25
- SA PRO: Top Long And Short Ideas, Monday November 18 Seeking Alpha Nov 19
- Northwest Biotherapeutics Poses Onyx Like Potential Seeking Alpha Nov 18
- The Immunotherapy Company You Never Saw Coming: Advaxis CSO Interview Seeking Alpha Nov 17
- How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors? Seeking Alpha Nov 13
- Combination Therapies Hold Key To Future Cancer Treatments Seeking Alpha Nov 12
IMUC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoCellular Therapeuti is up 47.47% over the last year vs S&P 500 Total Return up 30.24%, Northwest Biotherapeutics down 30.71%, and Advaxis down 46.52%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for IMUC
Pro Strategies Featuring IMUC
Did ImmunoCellular Therapeuti make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
ImmunoCellular Therapeutics Limited is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.